{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:09:36Z","timestamp":1774422576736,"version":"3.50.1"},"reference-count":16,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This research received funding from an anonymous non-pharma related individual in the form of donation.","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The fibroblast growth factor (FGF) signaling pathway plays a key role in tumorigenesis and is recognized as a potential therapeutic target. In this study, the authors aimed to assess the impact of serum FGF23 levels in the prognosis of patients with cancer and bone metastases from solid tumors. A cohort of 112 patients with cancer and metastatic bone disease were treated with bone-targeted agents (BTA). Serum baseline FGF23 was quantified by ELISA and dichotomized in FGF23high and FGF23low groups. Additionally, the association between FGF23 and overall survival (OS) and time to skeletal-related events (TTSRE) was investigated. Baseline characteristics were balanced between groups, except for the median urinary N-terminal telopeptide (uNTX) level. After a median follow-up of 26.0 months, a median OS of 34.4 and 12.2 months was found in the FGF23low and FGF23high groups, respectively (multivariate HR 0.18, 95% CI 0.07\u20130.44, p = 0.001; univariate HR 0.27, p = 0.001). Additionally, TTSRE was significantly longer for patients with FGF23low (13.0 vs. 2.0 months, p = 0.04). Overall, this study found that patients with FGF23low at baseline had longer OS and TTSRE. Further studies are warranted to define its role as a prognostic biomarker and in the use of drugs targeting the FGF axis.<\/jats:p>","DOI":"10.3390\/ijms20030695","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T11:51:12Z","timestamp":1549453872000},"page":"695","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-0838","authenticated-orcid":false,"given":"Andr\u00e9","family":"Mansinho","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, 1649-028 Lisbon, Portugal"},{"name":"Lu\u00eds Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"}]},{"given":"Arlindo R.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, 1649-028 Lisbon, Portugal"},{"name":"Lu\u00eds Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6917-4477","authenticated-orcid":false,"given":"Sandra","family":"Casimiro","sequence":"additional","affiliation":[{"name":"Lu\u00eds Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-7479","authenticated-orcid":false,"given":"Irina","family":"Alho","sequence":"additional","affiliation":[{"name":"Lu\u00eds Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"}]},{"given":"In\u00eas","family":"Vendrell","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, 1649-028 Lisbon, Portugal"}]},{"given":"Ana L\u00facia","family":"Costa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, 1649-028 Lisbon, Portugal"}]},{"given":"Rita","family":"Sousa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, 1649-028 Lisbon, Portugal"}]},{"given":"Catarina","family":"Abreu","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, 1649-028 Lisbon, Portugal"}]},{"given":"Catarina","family":"Pulido","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital da Luz, 1500-650 Lisbon, Portugal"}]},{"given":"Daniela","family":"Macedo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, 1649-028 Lisbon, Portugal"}]},{"given":"Teresa R.","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, 1649-028 Lisbon, Portugal"},{"name":"Lu\u00eds Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"}]},{"given":"Lurdes","family":"Correia","sequence":"additional","affiliation":[{"name":"Pathology Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, 1649-028 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-7318","authenticated-orcid":false,"given":"Lu\u00eds","family":"Costa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, 1649-028 Lisbon, Portugal"},{"name":"Lu\u00eds Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tig.2004.08.007","article-title":"Evolution of the FGF and FGFR gene families","volume":"20","author":"Itoh","year":"2004","journal-title":"Trends Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1006\/bbrc.2000.3696","article-title":"Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain","volume":"277","author":"Yamashita","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"37419","DOI":"10.1074\/jbc.M304544200","article-title":"Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX","volume":"278","author":"Liu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/en.2003-1768","article-title":"Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis","volume":"145","author":"Larsson","year":"2004","journal-title":"Endocrinology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1210\/en.2004-0233","article-title":"Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders","volume":"145","author":"Bai","year":"2004","journal-title":"Endocrinology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrendo.2009.196","article-title":"The FGF23-Klotho axis: Endocrine regulation of phosphate homeostasis","volume":"5","author":"Razzaque","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1210\/jc.2004-0724","article-title":"FGF-23 is elevated by chronic hyperphosphatemia","volume":"89","author":"Gupta","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17291","DOI":"10.18632\/oncotarget.4174","article-title":"FGF23 promotes prostate cancer progression","volume":"6","author":"Feng","year":"2015","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1158\/1078-0432.CCR-15-3086","article-title":"Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents","volume":"22","author":"Lipton","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6138","DOI":"10.1158\/1078-0432.CCR-17-1232","article-title":"Association of FGFR1 with ER\u03b1 Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer","volume":"23","author":"Formisano","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.18632\/oncotarget.14049","article-title":"Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors","volume":"8","author":"Feng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/13543784.2017.1287173","article-title":"FGFR-targeted therapeutics for the treatment of breast cancer","volume":"26","author":"Frezzetti","year":"2017","journal-title":"Expert Opin. Investig. Drugs"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/3\/695\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:31:15Z","timestamp":1760185875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/3\/695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["ijms20030695"],"URL":"https:\/\/doi.org\/10.3390\/ijms20030695","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]}}}